Kcab, compared clinical trial with Nexium

Comparison of equivalence with Nexium injection by twice a day

HK inno.N's new domestic drug ‘Kcab’ is specifically compared with the reference drug, Nexium.

 

The company said it will explore new indications through the trial.

 

The MFDS approved IND of Phase I clinical trial to explore the pharmacokinetics, Pharmacodynamic properties and safety of Tegoprazan twice a day dosing regimen in healthy subjects' submitted by HK inno.N on the 31st of last month.

 

64 healthy adults participated in this clinical trial.

 

It is interesting that the reference drug is Nexium injection.

 

In clinical trials, Kcab is administered twice a day to compare the pharmacokinetic and pharmacodynamic properties of Nexium injections.

 

Kcab is currently used in the market once a day.

 

AstraZeneca Korea's Nexium injection is a product administered intravenously once a day, and is mainly used when oral method is not appropriate.

 

.A company official said, "This trial is for exploring new indications." If so, it is presumed to be for the purpose of acquiring the indications possessed by Nexium through comparing the equivalence with Nexium

 

.Accurate indications of Nexium are in the case of adult ▲when oral method is not appropriate, as an alternative to oral therapy, GERD with severe esophagitis or severe symptoms due to gastroesophageal reflux, ▲Prevention of rebleeding after endoscopic treatment of acute hemorrhagic gastric ulcer or duodenal ulcer

 

.In addition, for children aged 1 to 18 years, ▲ when oral method is not appropriate, it is used as an alternative treatment with erosive reflux esophagitis or severe GERD

 

.It is observed that Kcab are attempting clinical trials to obtain indications for 'prevention of rebleeding after endoscopic treatment of acute hemorrhagic gastric ulcer or duodenal ulcer'

 

.K-Cap is currently providing indications including antibiotic therapy for the treatment of H

 

.pylori in patients with peptic ulcer and/or chronic atrophic gastritis, ▲ treatment of erosive GERD, ▲ treatment of non-erosive GERD

 

.Additional clinical trials for maintenance indications of patients with erosive GERD treatment confirmed through an endoscope and clinical trials to investigate the possibility of using NSAIDs in combination are also being conducted

 

.Kcab (Tegoprazan) is a P-CAB (Potassium-Competitive Acid Blocker)-based drug that has a mechanism of reversibly blocking a proton pump that secretes gastric acid from the stomach wall

 

.The industry analyzes that Kcab is leading the evolution of the P-CAB family by conducting clinical trials with PPI-based drugs such as Nexium as a reference drug

 

.So far, PPI drugs have led the market in GERD related diseases

 

.Meanwhile, Kcap has successfully increased sales by recording an outpatient’s prescription amount of ₩30.7 billion only in the first half of this year, based on UBIST

 

.